AAV1-Follistatin / Milo Biotechnology - LARVOL DELTA

Follistatin Mitigates Atherosclerosis Through Activation of Arginine Metabolism and Adipose Browning. (PubMed, Cells) - "Adeno-associated viral delivery of Fst (AAV1-FST344) in Ldlr-/- mice significantly reduced aortic lesion area, improved plasma lipid profiles, and decreased expression of adhesion (VCAM1) and inflammatory (iNOS, TNF-α) markers in white adipose tissue (WAT), liver, and heart...Furthermore, Fst gene delivery increased the expression of fibroblast growth factor 21 (Fgf21) and adiponectin (AdipoQ) in WAT. Collectively, these findings identify Fst as a novel anti-atherogenic regulator that protects against vascular disease by promoting adipose browning, improving lipid metabolism, and activating Arg1-mediated metabolic pathways."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • CD68 • FGF21 • TGFB1 • TNFA • VCAM1

AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. (PubMed, JCI Insight) - "Here, we report such a model - the tamoxifen-inducible FSHD mouse model called TIC-DUX4. AAV1.Follistatin significantly increased TIC-DUX4 muscle mass and strength even in the presence of DUX4 expression, suggesting that myostatin inhibition may be a promising approach to treat FSHD-associated weakness. We conclude that TIC-DUX4 mice are a relevant model to study DUX4 toxicity and, importantly, are useful in therapeutic development studies for FSHD."

Journal • Preclinical